slides · global inventory
Fraud Exposure
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,793
Current window 5,341-5,370
Pages 227
Rows per page 30
Framework
5,341-5,370 of 6,793
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
114
The red box highlights the specific data point (Week 0 to Week 13) where the pooling occurs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
115
The slide uses a red box and annotations to highlight the drop in sample size (n=125 to n=103) at week 13, suggesting data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
116
The slide uses a red box and arrow to draw attention to the increase in HbA1c between week 0 and week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
117
The slide uses a line chart with error bars to argue that the mean value hides adverse patient outcomes. It highlights the 1-standard deviation range and extrapolates to 2-standard deviations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
121
The slide uses a direct quote from a medical paper to highlight a discrepancy between the company's claim and the reported data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c values) have been altered.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
130
The slide uses a line chart with error bars to compare 'Original Data' vs 'New Data' to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
131
Uses a 'before-after' comparison to highlight data inconsistency as evidence of fraud.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
140
Uses red boxes and arrows to visually connect the contradictory data points.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
148
The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
168
The slide uses patient testimonials to contradict the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
171
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit